Evidence map›Paper›PMID 36344851›Full record

ArticleClinical journal of gastroenterology2023

Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma.

Yusuke Kawamura, Norio Akuta, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Licht Tominaga, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki and 7 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Yusuke KawamuraDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan. k-yusuke@toranomon.gr.jp.ORCID http://orcid.org/0000-0001-6148-0042
Norio AkutaDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Junichi ShindohDepartment of Gastroenterological Surgery, Hepatobiliary-Pancreatic Surgery Division, Toranomon Hospital, Tokyo, Japan.
Masaru MatsumuraDepartment of Gastroenterological Surgery, Hepatobiliary-Pancreatic Surgery Division, Toranomon Hospital, Tokyo, Japan.
Satoshi OkuboDepartment of Gastroenterological Surgery, Hepatobiliary-Pancreatic Surgery Division, Toranomon Hospital, Tokyo, Japan.
Licht TominagaRadiation Oncology Division, Department of Radiology, Toranomon Hospital, Tokyo, Japan.
Shunichiro FujiyamaDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Tetsuya HosakaDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Satoshi SaitohDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Hitomi SezakiDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Fumitaka SuzukiDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Yoshiyuki SuzukiDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Kenji IkedaDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Yasuji AraseDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Masaji HashimotoDepartment of Gastroenterological Surgery, Hepatobiliary-Pancreatic Surgery Division, Toranomon Hospital, Tokyo, Japan.
Takuyo KozukaRadiation Oncology Division, Department of Radiology, Toranomon Hospital, Tokyo, Japan.
Hiromitsu KumadaDepartment of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Toranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aims of this study were to evaluate the clinical impact of curative-intent subsequent treatment on overall prognosis in lenvatinib-treated hepatocellular carcinoma (HCC) patients.

methodsEighty-three consecutive patients with intrahepatic target nodules who received lenvatinib were reviewed. The clinical impact of curative-intent subsequent treatments was investigated through analysis of overall survival (OS) according to pathological deterioration stratified by mALBI grade.

resultsIn patients with mALBI grade 1 and 2a liver function, R0 resection and lenvatinib-transarterial chemoembolization (lenvatinib-TACE) sequential therapy resulted in significantly better OS compared with other, non-curative-intent subsequent therapy and lack of additional treatment (median OS, 37.6 vs 29.0 months and 17.1 vs 8.9 months, respectively; P < 0.001). Multivariate analysis confirmed that use of R0 resection and lenvatinib-TACE sequential therapy were associated with better OS (hazard ratio [HR], 0.021; P < 0.001 and 0.108; P < 0.001) compared with other, non-curative-intent subsequent treatment (HR 0.256; P = 0.010). In contrast, in patients with mALBI grade 2b liver function, multivariate analysis confirmed higher treatment efficacy for non-curative-intent subsequent treatment with respect to OS (HR 0.041; P < 0.001) compared with R0 resection and lenvatinib-TACE sequential therapy (HR 0.057; P = 0.027 and 0.063; P = 0.001).

conclusionCurative-intent subsequent treatment is more useful for HCC patients with better liver function (mALBI grade 1 and 2a) and intrahepatic target nodules who have received lenvatini b-based treatment.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsHumansPhenylurea CompoundsQuinolinesRetrospective StudiesTreatment OutcomelenvatinibPhenylurea CompoundsQuinolinesHepatocellular carcinomaLenvatinibLenvatinib-transarterial chemoembolization sequential therapySubsequent treatment

Identifiers

PMID36344851
OpenAlexW4308401414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.